Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

interferon beta-1a

- PMLiVE

Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

Cladribine capsules could become the first ever oral treatment for gMG

- PMLiVE

Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE

Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

The immune-mediated disease affects more than 2.9 million people worldwide

- PMLiVE

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

- PMLiVE

Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

- PMLiVE

Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

- PMLiVE

Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS

The neurological disorder affects approximately 2.9 million people globally

- PMLiVE

Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type

The companies entered into a licensing agreement for the candidate in December last year

- PMLiVE

Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS

Tolebrutinib is currently being evaluated in various forms of the neurological disorder

- PMLiVE

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links